A new platform for analyzing the structure of proteins in biopharmaceuticals.
Multi-Radical Protein Footprinting (MRPF™) Platform
This study is working on a new way to look at proteins in medicines to help make better treatments for patients, so they can get therapies that are more suited to their needs.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Gennext Technologies, INC. NIH-funded |
| Lab location | 1 site (Half Moon Bay, UNITED STATES) |
| Project ID | NIH-11092327 on NIH RePORTER |
What this research studies
This research focuses on developing the Multi-Radical Protein Footprinting (MRPF™) Platform, which aims to enhance the analysis of protein structures in biopharmaceuticals. By utilizing advanced techniques that involve labeling proteins with radicals, the research seeks to provide a more detailed understanding of protein interactions and structures. Patients may benefit from this research as it could lead to improved biopharmaceuticals and therapies tailored to their specific needs. The project builds on previous successes in protein analysis to create a more effective and user-friendly system.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are receiving or may benefit from biopharmaceutical treatments.
Not a fit: Patients who are not undergoing treatment with biopharmaceuticals or do not have conditions requiring such therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective biopharmaceuticals and personalized treatments for patients.
How similar studies have performed: Previous research has shown success with similar radical footprinting techniques, indicating a promising approach for this novel platform.
Where this research is happening
Half Moon Bay, UNITED STATES
- Gennext Technologies, INC. — Half Moon Bay, United States (Active)
Researchers
- Principal investigator: Weinberger, Scot Randy — Gennext Technologies, INC.
- Study coordinator: Weinberger, Scot Randy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.